SC Biosciences is to be the exclusive distributor of sensitive
tools for drug discovery with the announcement this week that it
will distribute in vivo imaging technology in Japan for US company
Applied Biosystems group, the world's number one maker of
gene-analysing equipment, warned on Tuesday that it would report
lower-than-expected fiscal third-quarter revenue and earnings due
to deteriorating business conditions.
In the second mass spectrometer news of the week, life science
product company Agilent Technologies has introduced an ion trap
mass spectrometer that is approximately 10 times more sensitive
than its predecessor, the company claims.
Drug target validation has become the critical step in maintaining
profitability for the pharmaceutical industry, claims a new report
from market research company Business Communications. Drug
developers must accelerate identification...
A new approach to identifying patterns in gene expression analysis
has been shown to be more effective than the most popular method in
a joint Penn State and University at Buffalo study, write US
scientists this week.
In its first progress report since adopting the EU strategy on life
sciences and biotechnology in 2002, the European Commission
yesterday indicated that the risk of diverging policies in Member
States could seriously hamper the effectiveness...
Drug development and biomedical company Thuris and Italian
pharmaceutical company Sigma-Tau Industrie Farmaceutiche Riunite on
Monday announced an expansion of their ongoing research
collaboration to develop compounds to combat brain...
An Edinburgh-based marine biotech business has been given a £50,000
(€73 000) boost in its bid to scour tidal areas such as rock pools
to find and develop new drugs and antibiotics, including a new
compound found to be active against...
In the second news of the day on a European life science company,
DSM announced this week that from now on it will supply
technologies and services for the initial development phases of new
medicines - supplementing its existing service...
Japanese company Kaken Pharmaceutical and US Elitra Pharmaceuticals
said yesterday that they are to collaborate on a multi-year
research project for the discovery and development of novel
US demand for combinatorial chemistry products and services is set
to increase by more than twelve per cent annually to reach $4
billion (€3.7bn) in 2006, according to a new report from market
analyst the Freedonia group.